Table 3.
HBOT C10 Hemodyanmic Data.
| Baseline | Dobutamine | Esmolol | Significance | |
|---|---|---|---|---|
| Heart Rate (bpm) | 444 ± 25.3 (6) | 532 ± 25.7 (6) | 406 ± 19.7 (5) | c |
| End-Systolic Pressure (mmHg) | 92.5 ± 4.47 (6) | 107 ± 4.14 (6) | 81.3 ± 3.99 (5) | c |
| End-Diastolic Pressure (mmHg) | 8.55 ± 0.864 (6) | 9.11 ± 0.584 (6) | 11.6 ± 0.75 (5) | |
| Maximum dP/dt (mmHg/s) | 6411 ± 566 (6) | 14436 ± 887 (6) | 4395 ± 193 (5) | a |
| Minimum dP/dt (mmHg/s) | 7242 ± 1059 (6) | 12142 ± 1369 (6) | 4628 ± 387 (5) | a,c,d |
| Tau (msec) | 8.34 ± 1.02 (6) | 5.92 ± 0.373 (6) | 12 ± 0.415 (5) | |
| End-Diastolic Volume (μl) | 44.7 ± 6.61 (6) | 35.4 ± 6.49 (6) | 56.1 ± 6.87 (5) | |
| End-Systolic Volume (μl) | 30.3 ± 5.36 (6) | 15.6 ± 3.64 (6) | 42.2 ± 8.11 (5) | |
| Cardiac Output (μl/min) | 8439 ± 975 (6) | 12669 ± 2339 (6) | 8808 ± 523 (5) | |
| PRSW (mmHg⋅μl/μl) | 59.9 ± 6.79 (6) | 76.8 ± 8.7 (6) | 30.5 ± 11.4 (5) |
Significant testing by three-way ANOVA with genotype, oxygen therapy protocol, and hemodynamic protocol treatment as factors with Tukey post-hoc test. a; signifies difference between baseline and dobutamine with HBOT protocol in C10 mice; b: signifies difference between baseline and esmolol with HBOT treatment in C10 mice; c: signifies an overall genotype effect; d: represents an overall difference between normoxia and HBOT treatment; e: represents an overall difference between HBOT and hyperoxic treatment.